CyFlow™ CD11a Purified

CyFlow™ CD11a Purified
Target Species: Human
Antigen: CD11a
Field of Interest: Immunophenotyping
Clone: MEM-83
Regulatory Status: RUO
Alternative Name: LFA-1
Application: Flow cytometry, Functional assays, Immunoprecipitation
Format/Fluorochrome: Purified
Species of Origin: Mouse
Clonality: monoclonal
Isotype: IgG1
Product number: CS703732

For Research Use Only

$120.00 USD*

Price excludes any applicable taxes plus shipping costs

Concentration Unit mg/mL Concentration 1 Quantity 0.1 mg Immunogen Human... more
CyFlow™ CD11a Purified
Concentration Unitmg/mL
Concentration1
Quantity0.1 mg
ImmunogenHuman peripheral blood lymphocytes
SpecifityThe mouse monoclonal antibody MEM-83 recognizes CD11a (α subunit of human LFA-1) antigen, a 170-180 kDa type I transmembrane glycoprotein expressed on B and T lymphocytes, monocytes, macrophages, neutrophils, basophils and eosinophils.
Background InformationCD11a (LFA-1 α) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the αLβ2 integrin. CD11a is implicated in activation of LFA-1 complex. LFA-1 is expressed on the plasma membrane of leukocytes in a low-affinity conformation. Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of LFA-1 to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3. LFA-1 is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions. Blocking of LFA-1 function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases. For example, humanized anti-LFA-1 antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation; binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity.
Storage BufferThe reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.1% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (Eds): Leucocyte Typing IV. Oxford·University·Press,·Oxford. 1989; 1‑1820. <·NLM·ID:·8914679·> | Landis RC, Bennett RI, Hogg N: A novel LFA‑1 activation epitope maps to the I domain. J·Cell·Biol. 1993·Mar; 120(6):1519‑27. <·PMID:·7680657·> | Landis RC, McDowall A, Holness CL, Littler AJ, Simmons DL, Hogg N: Involvement of the "I" domain of LFA‑1 in selective binding to ligands ICAM‑1 and ICAM‑3. J·Cell·Biol. 1994·Jul; 126(2):529‑37. <·PMID:·7518468·> | Sarantos MR, Raychaudhuri S, Lum AF, Staunton DE, Simon SI: Leukocyte function‑associated antigen 1‑mediated adhesion stability is dynamically regulated through affinity and valency during bond formation with intercellular adhesion molecule‑1. J·Biol·Chem. 2005·Aug·5; 280(31):28290‑8. <·PMID:·15955822·> | Giblin PA, Lemieux RM: LFA‑1 as a key regulator of immune function: approaches toward the development of LFA‑1‑based therapeutics. Curr·Pharm·Des. 2006; 12(22):2771‑95. <·PMID:·16918410·> | Kellersch B, Kolanus W: Membrane‑proximal signaling events in beta‑2 integrin activation. Results·Probl·Cell·Differ. 2006; 43:245‑57. <·PMID:·17068975·> | Fujii T, Takada-Takatori Y, Kawashima K: Roles played by lymphocyte function‑associated antigen‑1 in the regulation of lymphocytic cholinergic activity. Life·Sci. 2007·May·30; 80(24‑25):2320‑4. <·PMID:·17289088·>

Article successfully added.